Consensus report
Yüklə 349,78 Kb. Pdf görüntüsü
|
18 Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II) consensus report 1 3
52. Nguyen-Khac E, Cadranel JF, Thevenot T, Nousbaum JB. Review article: the utility of reagent strips in the diagnosis of infected ascites in cirrhotic patients. Aliment Pharmacol Ther. 2008;28:282–8. 53. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del- Arbol L, Castells L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrho- sis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–9. 54. Han G, Qi X, He C, Yin Z, Wang J, Xia J, Yang Z, et al. Tran- sjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol. 2011;54:78–88. 55. Rautou PE, Angermayr B, Garcia-Pagan JC, Moucari R, Peck-Radosavljevic M, Raffa S, Bernuau J, et al. Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes. J Hepatol. 2009;51:47–54. 56. Garcia-Pagan JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, Vizzini G, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135:808–15. 57. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–76. 58. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cir- rhosis. Gut. 2007;56:1310–8. 59. Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59:105–10. 60. Rajekar H, Chawla Y. Terlipressin in hepatorenal syndrome: evidence for present indications. J Gastroenterol Hepatol. 2011;26 Suppl 1:109–14. 61. Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-anal- ysis of randomized controlled trials. J Gastroenterol Hepa- tol. 2010;25:880–5. 62. Gluud LL, Christensen K, Christensen E, Krag A. System- atic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010;51:576–84. 63. Gerbes AL, Gulberg V, Sauerbruch T, Wiest R, Appenrodt B, Bahr MJ, Dollinger MM, et al. (German S 3-Guideline “ascites, spontaneous bacterial peritonitis, hepatorenal syndrome”). Z Gastroenterol. 2011;49:749–79. 64. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, et al. A randomized, prospective, dou- ble-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360–8. 65. Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci. 2008;53:830–5. 66. Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, Monescillo A, Soriano G, et al. Terlipressin and albu- min vs. albumin in patients with cirrhosis and hepatore- nal syndrome: a randomized study. Gastroenterology. 2008;134:1352–9. 67. Piano S, Morando F, Fasolato S, Cavallin M, Boscato N, Boccagni P, Zanus G, et al. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with ter- lipressin and albumin: a new exception to MELD score in the allocation system to liver transplantation? J Hepatol. 2011;55:491–6. 68. Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relation- ship of serum creatinine to hemodynamics. J Hepatol. 2011;55:315–21. 69. Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi A, Fagiuoli S, et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol. 2011;55(6):124–8. 70. Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatore- nal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology. 2009;137: 1179–81. 71. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syn- drome and predictors of response. Am J Gastroenterol. 2008;103:1689–97. 72. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55–64. 73. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, et al. Reversal of type 1 hepatore- nal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29:1690–7. 74. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, Guevara M, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatol- ogy. 2002;36:941–8. 75. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, et al. Long term outcome after tran- sjugular intrahepatic portosystemic stent-shunt in non- transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000;47:288–95. 76. Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, Garcia-Pagan JC, et al. Transjugular intrahepatic porto- systemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems (see comments). Hepatol- ogy. 1998;28:416–22. 77. Rossle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut. 2010;59:988–1000. 78. Rifai K, Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, et al. Extracorporeal liver support by fractionated plasma separation and adsorption (Pro- metheus) in patients with acute-on-chronic liver failure (HELIOS study): a prospective randomized controlled mul- ticenter study. J Hepatol. 2010;52:6A. 79. Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Doll- inger M. Relief Study Group. Extracorporeal liver support with the molecular absorbent recirculating system (MARS) in patients with acute-on-chronic liver failure (AOCLF). The RELIEF trial. J Hepatol. 2010;52:1184A. 80. Charlton MR, Wall WJ, Ojo AO, Gines P, Textor S, Shihab FS, Marotta P, et al. Report of the first international liver trans- plantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl. 2009;15:S1–34. 81. Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, et al. Primary prophylaxis of spontane- ous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818–24. 82. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637–48. consensus report Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II) 19 1 3
83. Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Bar- raud H, Saliba F, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology. 2010;138:1755–62. 84. Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol. 2006;12:2115–9. 85. Ogren M, Bergqvist D, Bjorck M, Acosta S, Sternby NH. High incidence of concomitant venous thromboembolism in patients with portal vein thrombosis: a population study based on 23,796 consecutive autopsies. J Thromb Haemost. 2007;5:198–200. 86. Sarin SK, Sollano JD, Chawla YK, Amarapurkar D, Hamid S, Hashizume M, Jafri W, et al. Consensus on extra-hepatic portal vein obstruction. Liver Int. 2006;26:512–19. 87. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J. Hepatol. 2003;38:364–71. 88. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on method- ology of diagnosis and therapy in portal hypertension. J. Hepatol. 2010;53:762–8. 89. Rajani R, Melin T, Bjornsson E, Broome U, Sangfelt P, Dan- ielsson A, Gustavsson A, et al. Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and sur- vival—an 18-year experience. Liver Int. 2009;29:253–9. 90. Smalberg JH, Koehler E, Darwish Murad S, Plessier A, Seijo S, Trebicka J, Primignani M, et al. The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood. 2011;117:3968–73. 91. Xavier SG, Gadelha T, Pimenta G, Eugenio AM, Ribeiro DD, Gomes FM, Bonamino M, et al. JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci. 2010;55:1770–7. 92. Tondeur S, Boutruche S, Biron-Andreani C, Schved JF. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study. Thromb Haemost. 2009;101:787–9. 93. Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Gran- done E, Guardascione MA, Brancaccio V, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost. 2007;5:55–61. 94. Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hag- glund H, Bandini G, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplanta- tion: a prospective cohort study of the European group for blood and marrow transplantation. European group for blood and marrow transplantation chronic leukemia work- ing party. Blood. 1998;92:3599–604. 95. Deleve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009;49:1729–64. 96. Tsochatzis EA, Senzolo M, Germani G, Gatt A, Burroughs AK. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther. 2010;31:366–74. 97. Hoekstra J, Janssen HL. Vascular liver disorders (I): diag- nosis, treatment and prognosis of Budd-Chiari syndrome. Neth J Med. 2008;66:334–9. 98. Hoekstra J, Janssen HL. Vascular liver disorders (II): portal vein thrombosis. Neth J Med. 2009;67:46–53. 99. Crawford JM. Vascular disorders of the liver. Clin Liver Dis. 2010;14:635–50. 100. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, et al. Guidelines for the diag- nosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hyper- tension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493–537. 101. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pul- monary-Hepatic vascular disorders (PHD). Eur Respir J. 2004;24:861–80. 102. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hyperten- sion: prevalence and relation to splanchnic hemodynam- ics. Gastroenterology. 1991;100:520–8. 103. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen- Solal A, Mal H, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a pro- spective study. Hepatology. 2003;37:401–9. 104. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut. 2003;52:1355–62. 105. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg. 1997;3:494–500. 106. Taura P, Garcia-Valdecasas JC, Beltran J, Izquierdo E, Navasa M, Sala-Blanch J, Mas A, et al. Moderate primary pulmonary hypertension in patients undergoing liver transplantation. Anesth Analg. 1996;83:675–80. 107. Castro M, Krowka MJ, Schroeder DR, Beck KC, Plevak DJ, Rettke SR, Cortese DA, et al. Frequency and clinical impli- cations of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc. 1996;71:543–51. 108. Plevak D, Krowka M, Rettke S, Dunn W, Southorn P. Suc- cessful liver transplantation in patients with mild to moderate pulmonary hypertension. Transplant Proc. 1993;25:1840. 109. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemo- dynamic manifestations. J Am Coll Cardiol. 1991;17:492–8. 110. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med. 1999;130:740–3. 111. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology. 1999;30:641–8. 112. Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoet- ter E, Pletz MW, Welte T, et al. Experience with inhaled ilo- prost and bosentan in portopulmonary hypertension. Eur Respir J. 2007;30:1096–102. 113. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, et al. Bosentan therapy for porto- pulmonary hypertension. Eur Respir J. 2005;25:502–8. 114. Tan HP, Markowitz JS, Montgomery RA, Merritt WT, Klein AS, Thuluvath PJ, Poordad FF, et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transpl. 2001;7:745–9. 115. Kett DH, Acosta RC, Campos MA, Rodriguez MJ, Quartin AA, Schein RM. Recurrent portopulmonary hypertension after liver transplantation: management with epopros- tenol and resolution after retransplantation. Liver Transpl. 2001;7:645–8. 20 Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II) consensus report 1 3
116. Plotkin JS, Kuo PC, Rubin LJ, Gaine S, Howell CD, Laurin J, Njoku MJ, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation. 1998;65:457–9. 117. Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, Ramsay M, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant. 2007;7:1258–64. 118. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, Grimminger F, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J. 2006;28:563–7. 119. Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endo- thelin receptor antagonist in portopulmonary hyper- tension: a safe and effective therapy? Gastroenterology. 2005;128:164–8. 120. Cartin-Ceba R, Swanson K, Iyer V, Wiesner RH, Krowka MJ. Safety and efficacy of ambrisentan for the treatment of por- topulmonary hypertension. Chest. 2011;139:109–14. 121. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O. Deleterious effects of beta-block- ers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006;130:120–6. 122. Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Rob- erts KE, Shah VH, et al. Impact of hepatopulmonary syn- drome on quality of life and survival in liver transplant candidates. Gastroenterology. 2008;135:1168–75. 123. Schenk P, Schoniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Muller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology. 2003;125:1042–52. 124. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: impact of liver transplanta- tion. Hepatology. 2005;41:1122–9. Document Outline
Yüklə 349,78 Kb. Dostları ilə paylaş:
|